Company: IMRX
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001790340-25-000135
Chunk: 338

Company: Immuneering Corp
Filing Date: 2025-11-12
Form: 10-Q
Item: Part I, Item 1
Chunk 338
---
 —— — — (14,079,927)(14,079,927)Other comprehensive loss—— —— — 1,084 — 1,084 Balance at June 30, 202429,653,355$29,653 —$— $257,922,316 $— $(191,646,334)$66,305,635 Issuance of common stock through employee stock purchase plan78,34178 —— 127,109 — — 127,187 Issuance of common stock under at-the-market offering, net of commissions, underwriting discounts and $86,374 in issuance costs1,318,7521,319 —— 4,236,078 — — 4,237,397 Stock-based compensation expense—— —— 1,640,116 — — 1,640,116 Net loss—— —— — — (14,597,366)(14,597,366)Other comprehensive income—— —— — 7,845 — 7,845 Balance at September 30, 202431,050,448$31,050 —$— $263,925,619 $7,845 $(206,243,700)$57,720,814 

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

10

Table of Contents

IMMUNEERING CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2025 and 2024

(Unaudited)

Nine Months Ended September 30,20252024Cash flows from operating activities:Net loss$(44,444,888)$(42,985,123)Adjustment to reconcile to net loss to net cash used in operating activities:  Depreciation and amortization expense248,628 269,691 Reduction in carrying amount of right-of-use assets255,660 247,165 Intangible asset amortization21,950 21,950 Stock-based compensation expense4,673,290 4,776,623 Net accretion of discount on marketable securities— (203,491)Loss on disposal of fixed assets— 1,315 Change in assets and liabilities:  (Increase) decrease in:  Prepaid expenses and other current